Incentives for global public health

By:

Pogge Thomas

Contributor(s):

Rimer Mathew Rubenstein Kim

Publication details: Cambridge Cambridge University Press 2010Description: 512p xixISBN:

9780521116565

Subject(s):

1. Drug - Organization & Administration - Legislation2. Drugs - Essential - Supply & Distribution3. Health Service Accessibility

DDC classification:

362.170000 POG

Contents:

Contents: Introduction: access to essential medicines: public health and international law Thomas Pogge, Matthew Rimmer and Kim Rubenstein; Part I. International Trade: 1. TRIPS and essential medicines: must one size fit all? Making the WTO responsive to the global health crisis Rochelle Cooper Dreyfuss; 2. The TRIPS waiver as a recognition of public health concerns in the WTO Andrew Mitchell and Tania Voon; 3. Public law challenges to the regulation of pharmaceutical patents in the US Bilateral Free Trade Agreements Hitoshi Nasu; 4. Global health and development: patents and public interest Elizabeth Siew Kuan Ng; Part II. Innovation: 5. The Health Impact Fund: boosting innovation without obstructing free access Thomas Pogge; 6. The Health Impact Fund: a critique Kathleen Liddell; 7. A prize system as a partial solution to the health crisis in the developing world William W. Fisher and Talha Syed; 8. Innovation and insufficient evidence: the case for a WTO-WHO agreement on health technology safety and cost-effectiveness evaluation Thomas Faunce; Part III. Intellectual Property: 9. Opening the dam: patent pools, innovation, and access to essential medicines Dianne Nicol and Jane Nielsen; 10. Open source drug discovery: a revolutionary paradigm or a utopian model? Krishna Ravi Srinivas; 11. Accessing and benefit sharing avian influenza viruses through the World Health Organisation: a CBD and TRIPS compromise thanks to Indonesia's sovereignty claim? Charles Lawson and Barbara Hocking; 12. The Lazarus effect: the (RED) campaign and creative capitalism Matthew Rimmer; Part IV. Health-Care: 13. Beyond TRIPS: the role of non-state actors and access to essential medicines Noah Benjamin Novogrodsky; 14. Securing health through rights Katharine Young; 15. The role of national laws in reconciling constitutional right to health with TRIPS obligations: an examination of the Glivec patent case in India Rajshree Chandra; 16. Tipping point: Thai compulsory licenses redefine essential medicines debate Jonathan Burton-MacLeod

Tags from this library: No tags from this library for this title. Log in to add tags.

Average rating: 0.0 (0 votes)

Holdings
Item type	Current library	Call number	Status	Date due	Barcode
BOOKs	National Law School	362.17 POG (Browse shelf(Opens below))	Available		33967

Browsing National Law School shelves Close shelf browser (Hides shelf browser)

Previous						No cover image available		Next
Previous	362.10683 SHO Health workforce governance : Improved access, good regulatory practice, safer patients	362.10954 GOE Managing customer satisfaction in the corporate hospitals /	362.10954 SAS Heal-thy India : Untold stories of healthcare	362.17 POG Incentives for global public health	362.19 FAL Economic impact of HIV/AIDS on households	362.198 SPA The baby business : How money, science and politics drive the commerce of conception	362.2 DAL Mental illness and learning disability since 1850 : Finding a place for mental disorder in the United Kingdom	Next

Contents:
Introduction: access to essential medicines: public health and international law Thomas Pogge, Matthew Rimmer and Kim Rubenstein;
Part I. International Trade:
1. TRIPS and essential medicines: must one size fit all? Making the WTO responsive to the global health crisis Rochelle Cooper Dreyfuss;
2. The TRIPS waiver as a recognition of public health concerns in the WTO Andrew Mitchell and Tania Voon;
3. Public law challenges to the regulation of pharmaceutical patents in the US Bilateral Free Trade Agreements Hitoshi Nasu;
4. Global health and development: patents and public interest Elizabeth Siew Kuan Ng;
Part II. Innovation:
5. The Health Impact Fund: boosting innovation without obstructing free access Thomas Pogge;
6. The Health Impact Fund: a critique Kathleen Liddell;
7. A prize system as a partial solution to the health crisis in the developing world William W. Fisher and Talha Syed;
8. Innovation and insufficient evidence: the case for a WTO-WHO agreement on health technology safety and cost-effectiveness evaluation Thomas Faunce;
Part III. Intellectual Property:
9. Opening the dam: patent pools, innovation, and access to essential medicines Dianne Nicol and Jane Nielsen;
10. Open source drug discovery: a revolutionary paradigm or a utopian model? Krishna Ravi Srinivas;
11. Accessing and benefit sharing avian influenza viruses through the World Health Organisation: a CBD and TRIPS compromise thanks to Indonesia's sovereignty claim? Charles Lawson and Barbara Hocking;
12. The Lazarus effect: the (RED) campaign and creative capitalism Matthew Rimmer;
Part IV. Health-Care:
13. Beyond TRIPS: the role of non-state actors and access to essential medicines Noah Benjamin Novogrodsky;
14. Securing health through rights Katharine Young;
15. The role of national laws in reconciling constitutional right to health with TRIPS obligations: an examination of the Glivec patent case in India Rajshree Chandra;
16. Tipping point: Thai compulsory licenses redefine essential medicines debate Jonathan Burton-MacLeod

There are no comments on this title.

to post a comment.